Diagnosed with chronic moderate to severe plaque psoriasis (psoriasis-involved body surface area (BSA) >= 3% and Psoriasis Area and Severity Index (PASI) score >= 3 at screening baseline)
Conditions
Interventions
Sponsors
People‘s Hospital of Xinjiang Uygur Autonomous Region
Eligibility
Sex/Gender
All
Age
18 Years to 100 Years
Inclusion criteria
Inclusion criteria: 1.Age >=18 years; 2.Diagnosed with chronic moderate to severe plaque psoriasis (with psoriasis affected area (BSA) >=3% and psoriasis area and severity index (PASI) score >=3 at screening baseline); 3.From the screening period until 6 months after the last drug administration, the subjects had no plans to give birth or donate sperm or eggs, and voluntarily adopted highly effective physical contraception measures; 4.Patients who are assessed by clinicians as suitable for treatment withXeligekimab and are intended to receive Xeligekimab for the first time; 5.Those who voluntarily participate and sign the informed consent form.
Exclusion criteria
Exclusion criteria: 1.During screening, patients with guttate, pustular, erythrodermic, or drug-induced psoriasis were excluded; 2.Allergic to the active ingredient or any adjuvant of CIMZIA; 3.Suffering from active tumors; 4.Women who are pregnant or breastfeeding; 5.The researchers evaluated other situations that were not suitable for inclusion in this study.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The proportion of subjects who achieve PASI 90 at week 12; | — |
Secondary
| Measure | Time frame |
|---|---|
| The proportion of patients who achieved a PASI score of 90 at weeks 4, 24, 36 and 52;The proportion of patients who achieved a PASI 75 and a PGA score of 0 or 1 at weeks 4, 12, 24, 36 and 52;The proportion of patients achieving a PGA 0 and PASI 100 response at weeks 4, 12, 24, 36 and 52;Changes in the Psoriasis Area and Severity Index (PASI) score and body surface area (BSA) relative to baseline at weeks 4, 12, 24, 36 and 52; | — |
Countries
China
Contacts
Public ContactKang Xiaojing
People‘s Hospital of Xinjiang Uygur Autonomous Region
Outcome results
None listed